<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529542</url>
  </required_header>
  <id_info>
    <org_study_id>19286</org_study_id>
    <nct_id>NCT00529542</nct_id>
  </id_info>
  <brief_title>A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol</brief_title>
  <official_title>A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the
      treatment of PCOS with elevated LDL cholesterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that improving the lipid profile with atorvastatin will improve
      vascular function, increase the frequency of ovulation, decrease androgen levels, improve
      insulin sensitivity, and improve the lipid profile more efficiently than placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial Artery Flow-mediated Dilation (FMD)</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Brachial artery FMD, the percent change in brachial artery diameter following release of transient occlusion, was selected as the primary outcome because it is the most widely used research tool for evaluating the effects of interventions on endothelial function. FMD has been shown to predict longterm cardiovascular events, even in patients with no apparent heart disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Brachial Artery Conductance (BAC)</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Pneumatic cuffs were positioned on the upper arm and wrist of the experimental arm. The brachial artery was imaged using an ATL Doppler ultrasound probe (5-12MHz linear array scanhead, HDI 5000, Advanced Technology Laboratories, Bothell, WA). Mean blood flow velocity (MBV) and brachial artery diameter (BAD) were recorded at baseline. Then the wrist cuff was inflated to 200-250 mmHg. After a minute, with the wrist cuff still inflated, the arm cuff was inflated to 200-250 mmHg. After 10 minutes the arm cuff was released to induce reactive hyperemia in the brachial artery. Upon release of the arm cuff, we continuously measured blood pressure (BP), heart rate (HR), and MBV, and intermittently measured BAD in the experimental arm. Brachial artery conductance (BAC)was calculated as MBV/MAP and FMD was calculated as percent change in BAD from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for Glucose During OGTT</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>A 75 gram oral glucose tolerance test (OGTT) was performed with blood draws at 0, 30, 60, 90 and 120 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for Insulin</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Area under the curve for insulin during OGTT: A 75 gram oral glucose tolerance test was performed with blood draws at 0, 30, 60, 90 and 120 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHEAS</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Dehydroepiandrosterone sulfate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>High-sensitivity C-reactive Protein (hsCRP)</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>high sensitive C-reactive protein as a measure of inflammation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipitor</intervention_name>
    <description>40mg caplets per day for six weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo caplet per day for six weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Women with PCOS

          -  8 or fewer menstrual periods per year

          -  elevated serum total testosterone

          -  elevated LDL cholesterol

        Exclusion Criteria:

          -  current pregnancy or breastfeeding

          -  current use of oral contraceptives, progestins

          -  insulin sensitizing medications

          -  thyroid disease, hyperprolactinemia, active liver disease, type 1 or type 2 diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Legro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center, College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pennstatehershey.org/web/obgyn/research</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>February 15, 2013</results_first_submitted>
  <results_first_submitted_qc>March 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2013</results_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Richard S. Legro, M.D.</investigator_full_name>
    <investigator_title>Professor, Obstetrics and Gynecology and Public Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through the clinics of the Departments of Medicine and Obstetrics and Gynecology at Penn State Hershey Medical Center from October 20, 2006 to September 8, 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>Atorvastatin, 40 mg qd</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo qd</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>Atorvastatin, 40 mg qd</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo qd</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brachial Artery Flow-mediated Dilation (FMD)</title>
        <description>Brachial artery FMD, the percent change in brachial artery diameter following release of transient occlusion, was selected as the primary outcome because it is the most widely used research tool for evaluating the effects of interventions on endothelial function. FMD has been shown to predict longterm cardiovascular events, even in patients with no apparent heart disease.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Flow-mediated Dilation (FMD)</title>
          <description>Brachial artery FMD, the percent change in brachial artery diameter following release of transient occlusion, was selected as the primary outcome because it is the most widely used research tool for evaluating the effects of interventions on endothelial function. FMD has been shown to predict longterm cardiovascular events, even in patients with no apparent heart disease.</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>% change in brachial artery diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="7.3"/>
                    <measurement group_id="O2" value="9.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="4.6"/>
                    <measurement group_id="O2" value="10.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was initiated as a pilot study with the goal of enrolling 19 women in each group, which we hypothesized would provide 80% power to detect an absolute difference in the change in FMD from baseline between the two groups (Atorvastatin vs. Placebo) of 3.75%, assuming a common standard deviation (SD) of 4%, using a two-sided, two-sample t-test with α=0.05. Recruitment was slow due to strict inclusion/ exclusion criteria so we analyzed our data after the first 20 women completed the study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <p_value_desc>All hypotheses tests were two-sided.</p_value_desc>
            <method>Linear mixed-effects models</method>
            <method_desc>Linear mixed-effects models were fit to continuous outcomes to assess the change from baseline to 6 weeks between groups.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>This analysis revealed that the required sample size was 235 subjects per group for 80% power to detect an absolute 2% increase in FMD with Atorvastatin vs. Placebo. We stopped the trial because we had insufficient funds for the required sample size.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Brachial Artery Conductance (BAC)</title>
        <description>Pneumatic cuffs were positioned on the upper arm and wrist of the experimental arm. The brachial artery was imaged using an ATL Doppler ultrasound probe (5–12MHz linear array scanhead, HDI 5000, Advanced Technology Laboratories, Bothell, WA). Mean blood flow velocity (MBV) and brachial artery diameter (BAD) were recorded at baseline. Then the wrist cuff was inflated to 200–250 mmHg. After a minute, with the wrist cuff still inflated, the arm cuff was inflated to 200–250 mmHg. After 10 minutes the arm cuff was released to induce reactive hyperemia in the brachial artery. Upon release of the arm cuff, we continuously measured blood pressure (BP), heart rate (HR), and MBV, and intermittently measured BAD in the experimental arm. Brachial artery conductance (BAC)was calculated as MBV/MAP and FMD was calculated as percent change in BAD from baseline.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Brachial Artery Conductance (BAC)</title>
          <description>Pneumatic cuffs were positioned on the upper arm and wrist of the experimental arm. The brachial artery was imaged using an ATL Doppler ultrasound probe (5–12MHz linear array scanhead, HDI 5000, Advanced Technology Laboratories, Bothell, WA). Mean blood flow velocity (MBV) and brachial artery diameter (BAD) were recorded at baseline. Then the wrist cuff was inflated to 200–250 mmHg. After a minute, with the wrist cuff still inflated, the arm cuff was inflated to 200–250 mmHg. After 10 minutes the arm cuff was released to induce reactive hyperemia in the brachial artery. Upon release of the arm cuff, we continuously measured blood pressure (BP), heart rate (HR), and MBV, and intermittently measured BAD in the experimental arm. Brachial artery conductance (BAC)was calculated as MBV/MAP and FMD was calculated as percent change in BAD from baseline.</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>ml/sec/mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.9"/>
                    <measurement group_id="O2" value="3.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.8"/>
                    <measurement group_id="O2" value="4.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.8" spread="39.0"/>
                    <measurement group_id="O2" value="202.8" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.0" spread="19.7"/>
                    <measurement group_id="O2" value="192.1" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-70.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-95.2</ci_lower_limit>
            <ci_upper_limit>-46.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Cholesterol</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.7" spread="24.6"/>
                    <measurement group_id="O2" value="131.3" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="19.3"/>
                    <measurement group_id="O2" value="118.8" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-57.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.3</ci_lower_limit>
            <ci_upper_limit>-35.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL Cholesterol</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>HDL Cholesterol</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="14.6"/>
                    <measurement group_id="O2" value="46.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="11.8"/>
                    <measurement group_id="O2" value="46.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.3" spread="84.9"/>
                    <measurement group_id="O2" value="125.5" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" spread="24.8"/>
                    <measurement group_id="O2" value="132.5" spread="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-82.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-126.2</ci_lower_limit>
            <ci_upper_limit>-38.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" spread="9.0"/>
                    <measurement group_id="O2" value="85.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" spread="8.5"/>
                    <measurement group_id="O2" value="88.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.4</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>uU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="10.1"/>
                    <measurement group_id="O2" value="16.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="11.8"/>
                    <measurement group_id="O2" value="15.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for Glucose During OGTT</title>
        <description>A 75 gram oral glucose tolerance test (OGTT) was performed with blood draws at 0, 30, 60, 90 and 120 minutes.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for Glucose During OGTT</title>
          <description>A 75 gram oral glucose tolerance test (OGTT) was performed with blood draws at 0, 30, 60, 90 and 120 minutes.</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg*minute/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15693" spread="2162"/>
                    <measurement group_id="O2" value="15309" spread="3692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16136" spread="2569"/>
                    <measurement group_id="O2" value="15448" spread="3165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>586</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1811</ci_lower_limit>
            <ci_upper_limit>2983</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC for Insulin</title>
        <description>Area under the curve for insulin during OGTT: A 75 gram oral glucose tolerance test was performed with blood draws at 0, 30, 60, 90 and 120 minutes.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>AUC for Insulin</title>
          <description>Area under the curve for insulin during OGTT: A 75 gram oral glucose tolerance test was performed with blood draws at 0, 30, 60, 90 and 120 minutes.</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>uU*minute/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12738" spread="10010"/>
                    <measurement group_id="O2" value="9338" spread="5208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17479" spread="11929"/>
                    <measurement group_id="O2" value="9132" spread="4466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3385</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-287</ci_lower_limit>
            <ci_upper_limit>7056</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Testosterone</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="16.9"/>
                    <measurement group_id="O2" value="92.3" spread="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="21.4"/>
                    <measurement group_id="O2" value="75.7" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.1</ci_lower_limit>
            <ci_upper_limit>27.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Androstenedione</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Androstenedione</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.8"/>
                    <measurement group_id="O2" value="3.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.9"/>
                    <measurement group_id="O2" value="4.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DHEAS</title>
        <description>Dehydroepiandrosterone sulfate</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>DHEAS</title>
          <description>Dehydroepiandrosterone sulfate</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1630.0" spread="873.1"/>
                    <measurement group_id="O2" value="1701.5" spread="681.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1326.4" spread="854.3"/>
                    <measurement group_id="O2" value="1739.5" spread="781.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-364.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-655.3</ci_lower_limit>
            <ci_upper_limit>-73.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>High-sensitivity C-reactive Protein (hsCRP)</title>
        <description>high sensitive C-reactive protein as a measure of inflammation</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>High-sensitivity C-reactive Protein (hsCRP)</title>
          <description>high sensitive C-reactive protein as a measure of inflammation</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="9.6"/>
                    <measurement group_id="O2" value="7.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="5.4"/>
                    <measurement group_id="O2" value="6.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Systolic Blood Pressure</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.8" spread="15.8"/>
                    <measurement group_id="O2" value="114.5" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.0" spread="13.2"/>
                    <measurement group_id="O2" value="111.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.9</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="14.8"/>
                    <measurement group_id="O2" value="64.6" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" spread="12.3"/>
                    <measurement group_id="O2" value="65.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Ovarian Volume</title>
        <description>Pelvic ultrasound was performed using the 6.5 megahertz (MHz) probe of an ATL 400 machine to characterize ovarian size and morphology. Since in vitro studies demonstrate that statins inhibit ovarian theca-interstitial cell proliferation, we hypothesized that statins might reduce ovarian volume in PCOS.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Ovarian Volume</title>
          <description>Pelvic ultrasound was performed using the 6.5 megahertz (MHz) probe of an ATL 400 machine to characterize ovarian size and morphology. Since in vitro studies demonstrate that statins inhibit ovarian theca-interstitial cell proliferation, we hypothesized that statins might reduce ovarian volume in PCOS.</description>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="8.8"/>
                    <measurement group_id="O2" value="25.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="7.0"/>
                    <measurement group_id="O2" value="25.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>13.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Body Mass Index</title>
        <time_frame>baseline and 6 weeks</time_frame>
        <population>All analyses were performed by intention-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Atorvastatin, 40 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo qd</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <population>All analyses were performed by intention-to-treat.</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="11.8"/>
                    <measurement group_id="O2" value="36.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="8.4"/>
                    <measurement group_id="O2" value="35.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>What is being compared for this analysis is the change from baseline for &quot;Atorvastatin&quot; to the change from baseline for &quot;Placebo.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Linear mixed-effects models</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>Atorvastatin, 40 mg qd</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo qd</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>gallbladder removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard S. Legro</name_or_title>
      <organization>Milton S. Hershey Medical Center</organization>
      <phone>717-531-8478</phone>
      <email>rsl1@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

